GenScript

largest B2B producer of plasmids and lentiviral libraries; screening on primary T-cells.

Country: China

ISO 9001 ISO 13485

Coverage

	CN	EU	US
crop-biotech	✓	✓	✓
foundries-design	✓	✓	✓
genome-engineering	✓	✓	✓

Regulatorsepafdaemanmpa

Verifiable facts

Fact	Value	Source
Headcount	6,165 employees (2025-12-31)	genscript.com · www1.hkexnews.hk
Revenue	US$959.5 million (group) (2025-12-31)	genscript.com · www1.hkexnews.hk
Revenue	US$388.7 million (ProBio segment) (2025-12-31)	prnewswire.com
Production site	Nanjing and Zhenjiang, China; Hopewell, New Jersey, USA (2023-01-01)	genscript.com · prnewswire.com · probiocdmo.com
Capacity	16,000L GMP manufacturing capacity; dedicated commercial GMP plasmid facility (6,400m²) in Zhenjiang; cGMP sgRNA/DNA payload facility expansions	genscript.com · prnewswire.com · probiocdmo.com
Certification	GMP compliant (FDA, EMA, NMPA, PMDA, MFDS)	genscript.com · probiocdmo.com
Regulatory approval	140+ IND clearances globally as of 2025; 60+ ongoing CMC projects	genscript.com · prnewswire.com · probiocdmo.com
Funding	Group cash/bank balances: US$843.1 million as of 2025-12-31 medium confidence	genscript.com · probiocdmo.com

Independent sources: prnewswire.com · probiocdmo.com · www1.hkexnews.hk

Technologies

Name	Cluster	Risk
CRISPR screening as a service	genome-engineering	Low	→
DNA synthesis & gene foundry	foundries-design	Low	→
iGEM infrastructure, BioBricks and standard genetic parts	foundries-design	Low	→
Strain engineering (synbio CRO)	crop-biotech	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.